September 24, 2018 — AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.
This transaction expands AngioDynamics’ growing oncology business by adding RadiaDyne’s early-stage, proprietary OARtrac real-time radiation dose monitoring platform and other oncology solutions, including the IsoLoc/ImmobiLoc and Alatus balloon stabilizing technologies.
RadiaDyne’s recently launched OARtrac system provides precise, real-time measurement via a proprietary intracavitary device. The system delivers critical dose feedback to medical and radiation oncologists, providing customized adaptive radiotherapy, reduced side effects, and improved clinical outcomes across all forms of radiation and photon beam therapy.
RadiaDyne’s endorectal technology, IsoLoc/ImmobiLoc, removes transient rectal gas using a patented gas-release tip and reliably reduces prostate motion and radiation toxicity. RadiaDyne’s Alatus Vaginal Balloon Packing System provides physicians with an improved method for optimal dosimetry protection and decreased complications. Both patient-centric technologies improve clinical outcomes and are used widely in practice today.
RadiaDyne’s trailing 12-months revenues exceeded $6 million, and the acquisition is expected to close by the end of September and be neutral to earnings on an adjusted basis.
Deutsche Bank Securities Inc. served as the exclusive financial advisor to AngioDynamics.
For more information: www.angiodynamics.com
October 30, 2026 
